TUSSIONEX PENNKINETIC Drug Patent Profile

Which patents cover Tussionex Pennkinetic, and what generic alternatives are available?

Tussionex Pennkinetic is a drug marketed by Ucb Inc and is included in one NDA.

The generic ingredient in TUSSIONEX PENNKINETIC is chlorpheniramine polistirex; hydrocodone polistirex. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the chlorpheniramine polistirex; hydrocodone polistirex profile page.

Summary for TUSSIONEX PENNKINETIC

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for TUSSIONEX PENNKINETIC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TUSSIONEX PENNKINETIC	Extended-release Capsules	chlorpheniramine polistirex; hydrocodone polistirex	8 mg/10 mg and 4 mg/5 mg	019111	1	2004-09-10

US Patents and Regulatory Information for TUSSIONEX PENNKINETIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	TUSSIONEX PENNKINETIC	chlorpheniramine polistirex; hydrocodone polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	019111-001	Dec 31, 1987		DISCN	Yes	No

International Patents for TUSSIONEX PENNKINETIC

See the table below for patents covering TUSSIONEX PENNKINETIC around the world.

Country	Patent Number	Title	Estimated Expiration
Philippines	20237	LIQUID PROLONGED RELEAGE PHARMACEUTICAL FORMULATION CONTAINING IONIC CONSTITUENTS
Germany	3478085
Austria	42894
Ireland	57445	LIQUID PROLONGED RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING IONIC CONSTITUENTS
South Africa	8404023
Canada	1221632	COMPOSES PHARMACEUTIQUES LIQUIDES A LIBERATION LENTE CONTENANT DES ELEMENTS IONIQUES (LIQUID PROLONGED RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING IONIC CONSTITUENTS)
Japan	H0688901

TUSSIONEX PENNKINETIC Market Analysis and Financial Projection

Last updated: February 3, 2026

What is TUSSIONEX PENNKINETIC?

Tussionex Pennkinetic is an extended-release combination drug that contains hydrocodone and chlorpheniramine. Marketed primarily as a cough suppressant and cold remedy, it is indicated for the relief of cough and upper respiratory symptoms associated with allergic and non-allergic conditions. The drug utilizes an extended-release formulation designed to provide sustained symptom control over 12 hours.

Market Overview and Demand Drivers

The global cough and cold remedies market was valued at approximately $17 billion in 2022. Growth is driven by heightened awareness of respiratory illnesses, especially during seasonal peaks and pandemic conditions. Hydrocodone-based products face narrow regulatory pathways due to their potential for abuse, affecting market accessibility.

Key factors influencing demand include:

• Population segments with respiratory diseases, predominantly adults aged 45 and older.
• Prescription trends in regions with high awareness of combination cough medicines.
• Regulatory restrictions on narcotic-containing cough suppressants.

Regulatory Status and Market Access

Tussionex Penkkinetic holds FDA approval in the United States and has similar approvals in multiple countries, with varying restrictions due to its hydrocodone content. It is classified as a Schedule III substance under the Controlled Substances Act, with prescription limits and monitoring requirements.

In the US, the product faces potential market entry barriers due to opioid regulations:

• Prescription quantity limits.
• Prescription monitoring programs.
• Stringent labeling and abuse-deterrent requirements.

In other markets like Europe, regulatory constraints are similar, with stricter controls in place for narcotic combination drugs.

Competitive Landscape

Major competitors include other extended-release cough suppressants and combination drugs, notably:

• Dextromethorphan-based products.
• Codeine-containing formulations.
• Non-narcotic alternatives like levodropropizine.

The market niche occupied by Tussionex Penkkinetic faces competitive threats from generic formulations and non-narcotic drugs with favorable safety profiles.

Patent and Intellectual Property Status

Tussionex Penkkinetic is protected by exclusive rights that expire around 2030 in key markets, with patents covering its extended-release formulation and combination specificities. Patent challenges or expiration could lead to generic competition, impacting pricing and market share.

Pricing and Reimbursement Dynamics

Pricing strategies vary by region. In the US, the average wholesale price (AWP) ranges between $4 and $8 per dose. Reimbursement policies mostly favor prescription drugs with clear indications and monitoring, but reimbursement decreases with concerns over misuse.

Market pricing will be affected by:

• Competition from generics.
• Practice patterns favoring non-narcotic alternatives.
• Regulatory changes impacting formulary inclusion.

Investment Fundamentals and Risks

Revenue Potential

• Estimated annual sales in the US could reach $300 million if capturing 10% of the cough cold segment.
• Growth depends on expanding indications and geographic penetration.

Development and Launch Risks

• Regulatory hurdles due to opioid classification.
• Potential for formulation redesigns to include abuse-deterrent features.
• Competition from non-narcotic therapies.

Patent and Market Entry Risks

• Patent expiry in early 2030s.
• Generic entrants could erode margins.

Market Penetration

• Challenges include prescriber bias against narcotics for cough.
• Overcoming regulatory restrictions.

Manufacturing and Supply Chain

• Reliance on controlled substance manufacturing complicates supply chain.
• Regulatory inspections and compliance are critical.

Financial Outlook

• Short-term revenues are constrained by regulatory and competitive pressures.
• Long-term growth hinges on patent extensions, new formulations, and expanded indications.

Strategic Considerations for Investors

• Focus on companies with proven track records in narcotic formulations and regulatory navigation.
• Evaluate pipeline assets that could replace or supplement Tussionex Penkkinetic.
• Assess regional regulatory trends that could expand or restrict market access.
• Weigh the impact of potential patent expirations against upcoming patent extensions or new formulations.

Key Takeaways

• Tussionex Penkkinetic is a niche, extended-release narcotic-based cough suppressant with limited growth due to regulatory and competitive pressures.
• The market faces headwinds from opioid regulations and consumer preference shifts toward non-narcotic therapies.
• Patent expiry and generic competition are critical risks for long-term profitability.
• The product's revenue potential hinges on controlling regulatory hurdles and expanding geographic access.
• Investment prospects depend on company strategy, pipeline development, and market adaptation.

FAQs

1. What is the main legal risk associated with Tussionex Penkkinetic?
Its hydrocodone component categorizes it as a Schedule III controlled substance, imposing strict prescribing and dispensing regulations, which can limit market access and increase compliance costs.

2. When do patent protections for Tussionex Penkkinetic expire?
Patents are expected to expire around 2030, after which generic formulations may enter the market.

3. How does the market size of cough suppressants influence Tussionex Penkkinetic's investment outlook?
A large and growing market offers revenue opportunities, but the narcotic classification constrains growth compared to non-narcotic alternatives.

4. What patent strategies could extend Tussionex Penkkinetic’s market viability?
Developing abuse-deterrent formulations or new delivery systems can extend exclusivity beyond current patent expiry dates.

5. How does competition from non-narcotic cough remedies impact Tussionex Penkkinetic?
Non-narcotic products with favorable safety profiles are preferred, reducing demand for narcotic-based options and heightening competitive pressure.

---

Sources:
[1] IQVIA data, 2022.
[2] FDA product approval documentation, 2015.
[3] United States Controlled Substances Act, 2023.
[4] MarketResearch.com, 2022.
[5] PatentScope database, 2023.